MedTrace Logo

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

NCT00860821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-10-28

No results posted yet for this study

Summary

The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)

Conditions

  • Healthy

Interventions

DRUG

AZD8309

oral solution 30 mg/g, dose: 300mg bid for 3 days

DRUG

AZD8309

oral solution 30 mg/g, dose: 300mg bid for 3 days

Sponsors & Collaborators

Principal Investigators

  • Lars Olaf Cardell · Department of Otorhinolaryngology, Malmö University Hospital, Sweden

  • Leif Eriksson · AstraZeneca R&D Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Completion
2009-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860821 on ClinicalTrials.gov